ROSETTA GOODSON-REDMOND: Open Payments
NPI 1508222993 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$741 in 26 payments from 12 companies in 2025. Trend: 2023 $24 · 2024 $95 · 2025 $741
Food & beverage: $656Education: $85
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $233 |
| Gilead Sciences, Inc. | 3 | $127 |
| ABBVIE INC. | 4 | $83 |
| Merck Sharp & Dohme LLC | 3 | $68 |
| Daiichi Sankyo Inc. | 2 | $51 |
| Karyopharm Therapeutics Inc. | 2 | $41 |
| AstraZeneca Pharmaceuticals LP | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Genentech USA, Inc. | 1 | $26 |
| PFIZER INC. | 1 | $22 |
Products named: ERLEADA, Trodelvy, VENCLEXTA, RYBREVANT, KEYTRUDA, XPOVIO, LIBTAYO, Enhertu.
Industry payments across GA — which companies pay providers there.
